Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Promising new treatment for hereditary breast/ovarian cancer

European scientists recently discovered a novel therapy to treat a subgroup of patients with hereditary breast/ovarian cancer. Both the EU and the US have approved an accelerated procedure to market this promising new treatment with few side effects.

20 Mar 2015

Chemical found in stinging nettles and ants could improve cancer drug

A cancer drug could be made 50 times more effective by a chemical found in stinging nettles and ants, new research finds.

20 Mar 2015

PARP inhibitors can be effective in broader group of patients

A pioneering class of drugs that target cancers with mutations in the BRCA breast cancer genes could also work against tumours with another type of genetic fault, a new study suggests.

20 Mar 2015

ImmunoCellular, PharmaCell sign manufacturing agreement for European production of ICT-107

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with PharmaCell B.V. to provide contract manufacturing services for the European production of ICT-107, a dendritic cell-based cancer immunotherapy in development as a potential treatment for glioblastoma (GBM).

19 Mar 2015

Hormone therapy does not safeguard post-menopausal women against cardiovascular disease

New evidence published today in the Cochrane Library shows that hormone replacement therapy does not protect post-menopausal women against cardiovascular disease, and may even cause an increased risk of stroke.

10 Mar 2015

Pre-clinical data on Novogen’s Cantrixil to be presented at two upcoming conferences

Novogen today announces that Professor Gil Mor MD PhD from Yale Medical School will be presenting pre-clinical data on the lead candidate product, Cantrixil, at two upcoming conferences.

6 Mar 2015

VolitionRx begins pilot study to assess feasibility of NuQ assays in detecting prostate cancer

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has initiated a pilot study to assess the feasibility of VolitionRx's proprietary NuQ assays in detecting prostate cancer.

5 Mar 2015

FDA grants Orphan Drug Designation to Oncolytics' REOLYSIN for treatment of peritoneal cancer

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of primary peritoneal cancers.

3 Mar 2015

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of fallopian tube cancer

2 Mar 2015

Researchers outline personalized surgical approach to ovarian cancer

A surgical algorithm developed and implemented by ovarian cancer specialists at The University of Texas MD Anderson Cancer Center dramatically increases the frequency of complete removal of all visible tumor - a milestone strongly tied to improved survival.

28 Feb 2015

Study finds racial disparities among children with Crohn's disease

A study published recently in the IBD Journal found significant differences in hospital readmissions, medication usage, and both medical and surgical complications of children with Crohn's disease related to race. In the study, black children had a 1.5 times higher frequency of hospital readmissions because of Crohn's disease compared to white children.

28 Feb 2015

New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

There are no effective available treatments for sufferers of Glioblastoma multiforme (GBM), the most aggressive and devastating form of brain tumor. The disease, always fatal, has a survival rate of only 6-18 months.

25 Feb 2015

Researchers find that new targeted drugs can attack weak spots in cancer cells

Scientists have identified weak spots in cancer cells that could be targeted and attacked by new precision drugs.

25 Feb 2015

Serous ovarian cancer is more deadly, shows Cancer Research UK study

THE most common type of ovarian cancer is more deadly if it consists of a patchwork of different groups of cells, according to a Cancer Research UK study published today (Tuesday) in PLOS Medicine.

25 Feb 2015

Epigenetics and women’s health research: an interview with Professor Steve Conlan, Swansea University

Our research into gynaecological oncology focuses around understanding mechanisms of how genes are regulated or how they become dysregulated in a disease; and also the effects that has on the surface of the endometrium and also the function of the ovaries...

From Chromatrap® - Porvair Sciences Ltd 24 Feb 2015

Majority of women support idea of more frequent breast screening for individuals at higher risk of cancer

Most women (85 per cent) would back the idea of more frequent breast screening if they are at higher genetic risk of developing breast cancer, according to research published today by The Breast.

20 Feb 2015

Oncolytics Biotech’s REOLYSIN receives Orphan Drug Designation for treatment of pancreatic cancer

Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of pancreatic cancer.

17 Feb 2015

Wistar researchers identify new therapeutic target for aggressive form of ovarian cancer

Ovarian cancer is the deadliest of all cancers affecting the female reproductive system with very few effective treatments available. Prognosis is even worse among patients with certain subtypes of the disease. Now, researchers at The Wistar Institute have identified a new therapeutic target in a particularly aggressive form of ovarian cancer, paving the way for what could be the first effective targeted therapy of its kind for the disease.

16 Feb 2015

New study finds promising target for future therapies to treat breast and ovarian cancer patients

The Food and Drug Administration's recent approval of the drug olaparib for ovarian cancer patients with inherited mutations in the genes BRCA1 or BRCA2 came as welcome news to the thousands of women now eligible to receive it. A new study by Dana-Farber Cancer Institute scientists indicates that the pool of patients who can benefit from the drug is potentially much wider - and offers a ready means of identifying them.

16 Feb 2015

Risk of ovarian cancer increased with even short-term HRT use

There has been much uncertainty regarding the risk of cancer associated with taking hormone replacement therapy (HRT) for the menopause. An analysis of all available evidence published in The Lancet today shows that HRT, even when taken for only a few years, significantly increases the risk of developing the two most common types of ovarian cancer.

13 Feb 2015

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Promising new treatment for hereditary breast/ovarian cancer

Chemical found in stinging nettles and ants could improve cancer drug

PARP inhibitors can be effective in broader group of patients

ImmunoCellular, PharmaCell sign manufacturing agreement for European production of ICT-107

Hormone therapy does not safeguard post-menopausal women against cardiovascular disease

Pre-clinical data on Novogen’s Cantrixil to be presented at two upcoming conferences

VolitionRx begins pilot study to assess feasibility of NuQ assays in detecting prostate cancer

FDA grants Orphan Drug Designation to Oncolytics' REOLYSIN for treatment of peritoneal cancer

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of fallopian tube cancer

Researchers outline personalized surgical approach to ovarian cancer

Study finds racial disparities among children with Crohn's disease

New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

Researchers find that new targeted drugs can attack weak spots in cancer cells

Serous ovarian cancer is more deadly, shows Cancer Research UK study

Epigenetics and women’s health research: an interview with Professor Steve Conlan, Swansea University

Majority of women support idea of more frequent breast screening for individuals at higher risk of cancer

Oncolytics Biotech’s REOLYSIN receives Orphan Drug Designation for treatment of pancreatic cancer

Wistar researchers identify new therapeutic target for aggressive form of ovarian cancer

New study finds promising target for future therapies to treat breast and ovarian cancer patients

Risk of ovarian cancer increased with even short-term HRT use

Innovation in neuroscience drug discovery - eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Innovation in neuroscience drug discovery - eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in